Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple Myeloma

American Journal of Clinical Pathology

Volumn 121, Issue 4, 2004, Pages 482-488

  Lin, Pei ^a,c   Owens, Rebecca ^a   Tricot, Guido ^b   Wilson, Carla S ^a,d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

CD138; Flow cytometry; Immunophenotype; Myeloma; Plasma cell; Syndecan 1

Indexed keywords

CD20 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; PREDNISONE; STEM CELL FACTOR RECEPTOR; SYNDECAN 1; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LIGHT SCATTERING; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

EID: 1642348370     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/74R4TB90BUWH27JX     Document Type: Article

References (21)

1. Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81:2658-2663.
2. Weisberger J, Wu CD, Liu Z, et al. Differential diagnosis of malignant lymphomas and related disorders by specific pattern of expression of immunophenotypic markers revealed by multiparameter flow cytometry (Review). Int J Oncol. 2000;17:1165-1177.
3. Almeida J, Orfao A, Ocqueteau M, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol. 1999;107:121-131.
4. Witzig TE, Kimlinger T, Stenson M, et al. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 1998;31:167-175.
5. Lima M, Teixeira MA, Fonseca S, et al. Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies. Blood Cells Mol Dis. 2000;26:634-645.
6. Rawstron A, Barrans S, Blythe D, et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol. 1999;104:138-143.
7. Wijdenes J, Clement C, Klein B, et al. CD138 (syndecan1) workshop panel reports. In: Kishimoto T, Kikutani H, Von dem Borne AEG, et al, eds. Leukocyte Typing VI: White Cell Differentiation Antigens. New York, NY: Garland Publishing; 1998:249-252.
8. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, et al. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol. 2001;14:1052-1058.
9. Wijdenes J, Vooijs WC, Clement C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol. 1996;94:318-323.
10. Horvathova M, Gaillard JP, Liautard J, et al. Identification of novel and specific antigens of human plasma cells by mAB. In: Schlossman SF, Boumsell L, Gilks WR, et al, eds. Leukocyte Typing V: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1995:713-714.
11. Jourdan M, Ferlin M, Legouffe E, et al. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol. 1998;100:637-646.
12. Ocqueteau M, Orfao A, Garcia-Sanz R, et al. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol. 1996;95:489-493.
13. Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97:46-55.
14. Dahl IM, Rasmussen T, Kauric G, et al. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol. 2002;116:273-277.
15. Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol. 2002;160:1293-1299.
16. Sahara N, Takeshita A, Shigeno K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol. 2002;117:882-885.
17. Barlogie B, Shaughnessy J, Munshi N, et al. Plasma cell myeloma. In: Beutler E, Lichtman MA, Coller BS, et al, eds. Williams Hematology. 6th ed. New York, NY: McGraw-Hill; 2001:1287.
18. Barlogie B, Alexanian R, Pershouse M, et al. Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest. 1985;76:765-769.
19. Braylan RC, Orfao A, Borowitz MJ, et al. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. Cytometry. 2001;46:23-27.
20. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol. 2000;27:79-85.
21. Kumar S, Kimlinger TK, Lust JA, et al. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood. 2003;102:1075-1077.